-
An integrative view on breast cancer signature panels
Introduction: Breast cancer is heterogeneous with distinct clinical outcomes. Diverse types of markers are available on the market for breast cancer prognosis, diagnosis, and... -
MOESM2 of A phase I study of high-dose rosuvastatin with standard dose erloti...
Additional file 2: Figure S2. Serum marker levels in Patient 11 who developed rhadbomyolysis on study. Baseline and Day 6 (erlotinib only) serum levels in the normal range for...
